Board Change • May 20
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Zhizhong Ma was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Declared Dividend • May 20
Dividend of HK$0.30 announced Shareholders will receive a dividend of HK$0.30. Ex-date: 9th June 2026 Payment date: 13th July 2026 Dividend yield will be 2.5%, which is lower than the industry average of 8.1%. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 13% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 67% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Duyuru • Mar 05
Dongyue Group Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 Dongyue Group Limited announced that they will report fiscal year 2025 results on Mar 25, 2026 Duyuru • Jan 02
Dongyue Group Limited Announces Nomination Committee Appointments, Effective 31 December 2025 The board of directors of Dongyue Group Limited announced that Ms. Chung Tak Lai (Ms. Chung), an executive Director, and Mr. Ma Zhizhong (Mr. Ma), an independent non-executive Director, have been appointed as members of the nomination committee of the Company with effect from 31 December 2025. Following the appointment of Ms. Chung and Mr. Ma, the Nomination Committee has one Director of a different gender, and still comprises a majority of independent non-executive Directors. The above change in composition of the Nomination Committee is implemented in response to the amended Corporate Governance Code as set forth in Appendix C1 to the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the ``Stock Exchange'') which is currently in effect. Duyuru • Jul 25
Dongyue Group Limited to Report First Half, 2025 Results on Aug 26, 2025 Dongyue Group Limited announced that they will report first half, 2025 results on Aug 26, 2025 Duyuru • Jun 05
Dongyue Group Limited Approves Final Dividend for the Year Ended 31 December 2024 Dongyue Group Limited at the Annual General Meeting held on 5 June 2025, approved declared a final dividend of HKD 0.10 per Share for the year ended 31 December 2024. Duyuru • Feb 24
Dongyue Group Limited to Report Fiscal Year 2024 Results on Mar 27, 2025 Dongyue Group Limited announced that they will report fiscal year 2024 results on Mar 27, 2025 Reported Earnings • Sep 29
First half 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 1H 2023) First half 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 1H 2023). Revenue: CN¥7.26b (flat on 1H 2023). Net income: CN¥307.6m (up 8.4% from 1H 2023). Profit margin: 4.2% (up from 3.9% in 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings. Buy Or Sell Opportunity • Sep 26
Now 28% overvalued Over the last 90 days, the stock has fallen 18% to HK$6.95. The fair value is estimated to be HK$5.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 17%. Revenue is forecast to grow by 44% in 2 years. Earnings are forecast to grow by 208% in the next 2 years. Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$6.37, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$5.40 per share. Reported Earnings • Aug 30
First half 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 1H 2023) First half 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 1H 2023). Revenue: CN¥7.26b (flat on 1H 2023). Net income: CN¥307.6m (up 8.4% from 1H 2023). Profit margin: 4.2% (up from 3.9% in 1H 2023). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Duyuru • Aug 02
Dongyue Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Dongyue Group Limited announced that they will report first half, 2024 results on Aug 28, 2024 Duyuru • Jun 08
Dongyue Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Dongyue Group Limited at its annual general meeting held on June 6, 2024, approved a final dividend of HKD 0.10 per Share for the year ended 31 December 2023. Upcoming Dividend • Jun 04
Upcoming dividend of HK$0.10 per share Eligible shareholders must have bought the stock before 11 June 2024. Payment date: 12 July 2024. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (4.8%). Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to HK$8.73, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$4.99 per share. Reported Earnings • May 02
Full year 2023 earnings released: EPS: CN¥0.32 (vs CN¥1.73 in FY 2022) Full year 2023 results: EPS: CN¥0.32 (down from CN¥1.73 in FY 2022). Revenue: CN¥14.5b (down 28% from FY 2022). Net income: CN¥707.8m (down 82% from FY 2022). Profit margin: 4.9% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Declared Dividend • Mar 29
Dividend of HK$0.10 announced Shareholders will receive a dividend of HK$0.10. Ex-date: 11th June 2024 Payment date: 12th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 8.1%. Payout Ratios Payout ratio: 28%. Cash payout ratio: 60%. Duyuru • Mar 27
Dongyue Group Limited, Annual General Meeting, Jun 06, 2024 Dongyue Group Limited, Annual General Meeting, Jun 06, 2024. Reported Earnings • Mar 27
Full year 2023 earnings released: EPS: CN¥0.32 (vs CN¥1.73 in FY 2022) Full year 2023 results: EPS: CN¥0.32 (down from CN¥1.73 in FY 2022). Revenue: CN¥14.5b (down 28% from FY 2022). Net income: CN¥707.8m (down 82% from FY 2022). Profit margin: 4.9% (down from 19% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 7.3% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 02
Dongyue Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Dongyue Group Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 New Risk • Feb 29
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.9% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (448% cash payout ratio). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to HK$6.56, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$5.09 per share. Buy Or Sell Opportunity • Feb 20
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to HK$6.56. The fair value is estimated to be HK$5.09, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to decline by 3.4% in a year. Earnings are forecast to decline by 43% in the next year. Buy Or Sell Opportunity • Jan 25
Now 21% overvalued Over the last 90 days, the stock has fallen 4.8% to HK$5.75. The fair value is estimated to be HK$4.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 46%. Revenue is forecast to decline by 3.4% in a year. Earnings are forecast to decline by 43% in the next year. New Risk • Dec 21
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 17% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Minor Risks Dividend is not well covered by cash flows (448% cash payout ratio). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$6.39, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$4.13 per share. Reported Earnings • Sep 16
First half 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.76 in 1H 2022) First half 2023 results: EPS: CN¥0.13 (down from CN¥0.76 in 1H 2022). Revenue: CN¥7.20b (down 29% from 1H 2022). Net income: CN¥283.9m (down 83% from 1H 2022). Profit margin: 3.9% (down from 17% in 1H 2022). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 08
Dongyue Group Limited to Report First Half, 2023 Results on Aug 25, 2023 Dongyue Group Limited announced that they will report first half, 2023 results on Aug 25, 2023 Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to HK$7.30, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$12.72 per share. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to HK$5.67, the stock trades at a forward P/E ratio of 4x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 96% over the past three years. Duyuru • Jun 15
Dongyue Group Limited Provides Earnings Guidance for the Six Months Ending 30 June, 2023 Dongyue Group Limited provided earnings guidance for the six months ending 30 June, 2023. For the period, the Board expected that the Group may record a significant decrease in its net profit attributable to owners of the Company, as compared with that for the six months ended 30 June 2022. Upcoming Dividend • Jun 07
Upcoming dividend of HK$0.60 per share at 8.2% yield Eligible shareholders must have bought the stock before 14 June 2023. Payment date: 13 July 2023. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 8.2%. Within top quartile of Hong Kong dividend payers (7.7%). In line with average of industry peers (7.6%). Reported Earnings • Mar 29
Full year 2022 earnings released: EPS: CN¥1.73 (vs CN¥0.98 in FY 2021) Full year 2022 results: EPS: CN¥1.73 (up from CN¥0.98 in FY 2021). Revenue: CN¥20.0b (up 26% from FY 2021). Net income: CN¥3.86b (up 86% from FY 2021). Profit margin: 19% (up from 13% in FY 2021). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 41% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Director Zhizhong Ma was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improved over the past week After last week's 18% share price gain to HK$8.08, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 4x in the Chemicals industry in Hong Kong. Total returns to shareholders of 128% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$6.69 per share. Reported Earnings • Aug 24
First half 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.29 in 1H 2021) First half 2022 results: EPS: CN¥0.76 (up from CN¥0.29 in 1H 2021). Revenue: CN¥10.1b (up 56% from 1H 2021). Net income: CN¥1.69b (up 181% from 1H 2021). Profit margin: 17% (up from 9.3% in 1H 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 1.1% compared to a 2.7% growth forecast for the Chemicals industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jun 07
Upcoming dividend of HK$0.34 per share Eligible shareholders must have bought the stock before 14 June 2022. Payment date: 15 July 2022. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 3.0%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (5.3%). Valuation Update With 7 Day Price Move • May 19
Investor sentiment improved over the past week After last week's 16% share price gain to HK$9.80, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 130% over the past three years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 16% share price gain to HK$9.45, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 105% over the past three years. Reported Earnings • Apr 28
Full year 2021 earnings released: EPS: CN¥0.98 (vs CN¥0.38 in FY 2020) Full year 2021 results: EPS: CN¥0.98 (up from CN¥0.38 in FY 2020). Revenue: CN¥15.8b (up 58% from FY 2020). Net income: CN¥2.07b (up 169% from FY 2020). Profit margin: 13% (up from 7.7% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 12% growth forecast for the industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Zhizhong Ma was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment deteriorated over the past week After last week's 17% share price decline to HK$9.12, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 62% over the past three years. Board Change • Mar 22
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Zhizhong Ma was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improved over the past week After last week's 16% share price gain to HK$10.66, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 132% over the past three years. Valuation Update With 7 Day Price Move • Dec 03
Investor sentiment deteriorated over the past week After last week's 21% share price decline to HK$13.14, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 251% over the past three years. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to HK$15.18, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 297% over the past three years. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment improved over the past week After last week's 21% share price gain to HK$17.92, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 357% over the past three years. Recent Insider Transactions • Oct 16
CFO, VP & Executive Director recently bought HK$1.5m worth of stock On the 12th of October, Zhefeng Zhang bought around 100k shares on-market at roughly HK$14.72 per share. This was the largest purchase by an insider in the last 3 months. This was Zhefeng's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment deteriorated over the past week After last week's 22% share price decline to HK$18.44, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 308% over the past three years. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment deteriorated over the past week After last week's 19% share price decline to HK$21.60, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 394% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$13.77 per share. Reported Earnings • Sep 02
First half 2021 earnings released: EPS CN¥0.29 (vs CN¥0.20 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: CN¥6.47b (up 40% from 1H 2020). Net income: CN¥603.2m (up 49% from 1H 2020). Profit margin: 9.3% (up from 8.7% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 68% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment improved over the past week After last week's 34% share price gain to HK$21.55, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 344% over the past three years. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥16.52, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 218% over the past three years. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥11.40, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 5x in the Chemicals industry in Hong Kong. Total returns to shareholders of 104% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$9.88 per share. Recent Insider Transactions • Jul 08
Executive Director recently sold HK$3.7m worth of stock On the 7th of July, Jian Zhang sold around 397k shares on-market at roughly HK$9.20 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought HK$37m more than they sold in the last 12 months. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥6.50, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 6x in the Chemicals industry in Hong Kong. Total returns to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.46 per share. Upcoming Dividend • Jun 08
Upcoming dividend of HK$0.14 per share Eligible shareholders must have bought the stock before 15 June 2021. Payment date: 16 July 2021. Trailing yield: 2.3%. Lower than top quartile of Hong Kong dividend payers (6.0%). Lower than average of industry peers (3.5%). Reported Earnings • Apr 18
Full year 2020 earnings released: EPS CN¥0.38 (vs CN¥0.70 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.0b (down 23% from FY 2019). Net income: CN¥772.2m (down 47% from FY 2019). Profit margin: 7.7% (down from 11% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Executive Departure • Mar 12
Executive Director has left the company On the 11th of March, Chuanqi Liu's tenure as Executive Director ended after 14.6 years in the role. We don't have any record of a personal shareholding under Chuanqi's name. A total of 2 executives have left over the last 12 months. Executive Departure • Mar 12
Independent Non Executive Director has left the company On the 11th of March, Rundong Yue's tenure as Independent Non Executive Director ended after 13.3 years in the role. We don't have any record of a personal shareholding under Rundong's name. A total of 2 executives have left over the last 12 months. Reported Earnings • Mar 10
Full year 2020 earnings released: EPS CN¥0.37 (vs CN¥0.70 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥10.0b (down 23% from FY 2019). Net income: CN¥772.2m (down 47% from FY 2019). Profit margin: 7.7% (down from 11% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥7.03, the stock is trading at a trailing P/E ratio of 11.8x, up from the previous P/E ratio of 9.8x. This compares to an average P/E of 10x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 90%. Is New 90 Day High Low • Mar 02
New 90-day high: HK$7.03 The company is up 65% from its price of HK$4.25 on 02 December 2020. The Hong Kong market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥5.38, the stock is trading at a trailing P/E ratio of 9x, down from the previous P/E ratio of 11.1x. This compares to an average P/E of 9x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 65%. Is New 90 Day High Low • Jan 25
New 90-day high: HK$6.68 The company is up 113% from its price of HK$3.13 on 28 October 2020. The Hong Kong market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 45% over the same period. Is New 90 Day High Low • Jan 07
New 90-day high: HK$6.26 The company is up 106% from its price of HK$3.04 on 09 October 2020. The Hong Kong market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 30% over the same period. Valuation Update With 7 Day Price Move • Dec 30
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥6.18, the stock is trading at a trailing P/E ratio of 10.5x, up from the previous P/E ratio of 8.5x. This compares to an average P/E of 9x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 47%. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥5.58, the stock is trading at a trailing P/E ratio of 9.5x, up from the previous P/E ratio of 7.6x. This compares to an average P/E of 8x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 38%. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥4.88, the stock is trading at a trailing P/E ratio of 8.3x, up from the previous P/E ratio of 7x. This compares to an average P/E of 8x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 24%. Is New 90 Day High Low • Dec 17
New 90-day high: HK$4.45 The company is up 43% from its price of HK$3.12 on 18 September 2020. The Hong Kong market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 20% over the same period. Valuation Update With 7 Day Price Move • Nov 12
Market bids up stock over the past week After last week's 19% share price gain to CN¥3.85, the stock is trading at a trailing P/E ratio of 6.6x, up from the previous P/E ratio of 5.6x. This compares to an average P/E of 8x in the Chemicals industry in Hong Kong. Total returns to shareholders over the past year are 7.2%. Is New 90 Day High Low • Nov 09
New 90-day high: HK$3.55 The company is up 5.0% from its price of HK$3.38 on 11 August 2020. The Hong Kong market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 8.0% over the same period. Valuation Update With 7 Day Price Move • Nov 06
Market bids up stock over the past week After last week's 16% share price gain to CN¥3.43, the stock is trading at a trailing P/E ratio of 5.9x, up from the previous P/E ratio of 5x. This compares to an average P/E of 7x in the Chemicals industry in Hong Kong. Total return to shareholders over the past year is a loss of 11%. Recent Insider Transactions • Sep 24
CEO & Chairman recently bought HK$40m worth of stock On the 17th of September, Jianhong Zhang bought around 19m shares on-market at roughly HK$2.16 per share. This was the largest purchase by an insider in the last 3 months. This was Jianhong's only on-market trade for the last 12 months. Is New 90 Day High Low • Sep 24
New 90-day low: HK$3.00 The company is down 3.0% from its price of HK$3.10 on 24 June 2020. The Hong Kong market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is flat over the same period.